162 related articles for article (PubMed ID: 36579667)
1. EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models.
Qiu Y; Qi Z; Wang Z; Cao Y; Lu L; Zhang H; Mathes D; Pomfret EA; Lu SL; Wang Z
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36579667
[TBL] [Abstract][Full Text] [Related]
2. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
Qi Z; Qiu Y; Wang Z; Zhang H; Lu L; Liu Y; Mathes D; Pomfret EA; Gao D; Lu SL; Wang Z
Mol Oncol; 2021 Apr; 15(4):1054-1068. PubMed ID: 33540470
[TBL] [Abstract][Full Text] [Related]
3. Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1.
Potala S; Verma RS
Mol Biol Rep; 2011 Feb; 38(2):1389-97. PubMed ID: 20814829
[TBL] [Abstract][Full Text] [Related]
4. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
[TBL] [Abstract][Full Text] [Related]
5. Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.
Waldron NN; Oh S; Vallera DA
Oral Oncol; 2012 Dec; 48(12):1202-7. PubMed ID: 22818892
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
7. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
8. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
9. Ontak-like human IL-2 fusion toxin.
Wang Z; Zheng Q; Zhang H; Bronson RT; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2017 Sep; 448():51-58. PubMed ID: 28551309
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
11. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
12. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
13. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
Pickhard AC; Margraf J; Knopf A; Stark T; Piontek G; Beck C; Boulesteix AL; Scherer EQ; Pigorsch S; Schlegel J; Arnold W; Reiter R
BMC Cancer; 2011 Sep; 11():388. PubMed ID: 21896192
[TBL] [Abstract][Full Text] [Related]
15. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
17. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
[TBL] [Abstract][Full Text] [Related]
18.
Nair S; Bonner JA; Bredel M
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409179
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.
Peraino JS; Zhang H; Rajasekera PV; Wei M; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2014 Mar; 405():57-66. PubMed ID: 24462799
[TBL] [Abstract][Full Text] [Related]
20. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]